71995-54-5

Usage

Uses

Used in Pharmaceutical Industry:
CYCLOHEXYLOXY-ACETIC ACID is used as an intermediate in the synthesis of various pharmaceuticals for its ability to be incorporated into the structure of different drugs, enhancing their properties and effectiveness.
Used in Organic Chemistry:
CYCLOHEXYLOXY-ACETIC ACID is used as a building block in the synthesis of organic compounds, contributing to the development of new chemical entities with specific functions and applications.
Used in Inflammation and Pain Treatment:
CYCLOHEXYLOXY-ACETIC ACID is used as a potential therapeutic agent for its potential to treat inflammation and pain, providing an alternative approach to managing these conditions.
Used in Prodrug Development:
CYCLOHEXYLOXY-ACETIC ACID is used as a component in the production of prodrugs for the controlled release of active pharmaceutical ingredients, allowing for more targeted and efficient drug delivery.
Used in Materials Science:
CYCLOHEXYLOXY-ACETIC ACID is used in the synthesis of polymers and materials with specific properties, contributing to the development of advanced materials for various applications.

InChI:InChI=1/C8H14O3/c9-8(10)6-11-7-4-2-1-3-5-7/h7H,1-6H2,(H,9,10)

Upstream product

• 22096-22-6 sodium cyclohexanolate 
• 79-11-8 chloroacetic acid 
• 108-93-0 cyclohexanol 
• 122-59-8 2-phenoxyacetic acid 
• 3926-62-3 sodium monochloroacetic acid 
• 79-08-3 bromoacetic acid 
• 57941-70-5 ethyl 2-(cyclohexyloxy)acetate 
• 105-36-2 ethyl bromoacetate 
• 623-73-4 diazoacetic acid ethyl ester 

Downstream Products

• 1817-88-5 2-Cyclohexyloxyethanol 
• 106321-05-5 6-chloro-3-cyclohexyloxymethyl-1,1-dioxo-1,2(4)-dihydro-1λ⁶-benzo[1,2,4]thiadiazine-7-sulfonic acid amide 
• 191337-81-2 2-(cyclohexyloxy)acetyl chloride 
• 189955-80-4 cyclohexyloxy-acetic acid 2-(4-methanesulfonyl-phenyl)-1,1-dimethyl-2-oxo-ethyl ester 
• 90226-63-4 2-(cyclohexyloxy)ethylamine 
• 98552-43-3 2-(cyclohexyloxy)acetamide 
• 1616074-90-8 2-(cyclohexyloxy)-N-(3-(3,4-dihydroisoquinolin-2(1H)-yl)-2-hydroxypropyl)acetamide 
• 53067-04-2 2-(cyclohexyloxy)ethylchloride 
• 42604-09-1 (methoxymethoxy)cyclohexane 
• 1346127-39-6 2-(cyclohexyloxy)-N-{4-[({[(5-methyl-1,2,3-thiadiazol-4-yl)(phenyl)methylene]amino}oxy)methyl]-1,3-thiazol-2-yl}acetamide 
• 932-92-3 cyclohexyl ethyl ether 
• 86867-75-6 4-Methoxy-benzenesulfonic acid 3-cyclohexyloxy-2-oxo-propyl ester 
• 86867-74-5 Toluene-4-sulfonic acid 3-cyclohexyloxy-2-oxo-propyl ester 
• 86867-72-3 3-cyclohexyloxy-2-oxopropyl benzenesulfonate 

Relevant academic research and scientific papers

Photosensitized Intermolecular Carboimination of Alkenes through the Persistent Radical Effect

An intermolecular, two-component vicinal carboimination of alkenes has been accomplished by energy transfer catalysis. Oxime esters of alkyl carboxylic acids were used as bifunctional reagents to generate both alkyl and iminyl radicals. Subsequently, addition of the alkyl radical to an alkene generates a transient radical for selective radical–radical cross-coupling with the persistent iminyl radical. Furthermore, this process provides direct access to aliphatic primary amines and α-amino acids by simple hydrolysis.

Production device and method of high-content cyclic Grifola ester synthetic perfume (by machine translation)

The invention discloses a production device of high-content cyadoop synthetic perfume and a method for, producing the cyclohexyloxy acetic acid through the saponification, and O - H acidification of, the high-content cyclic Grifola (, cyclohexanone). (by machine translation)

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described.

N-(3-(2-(4-CHLOROPHENOXY)ACETAMIDO)BICYCLO[1.1.1]PENTAN-1-YL)-2-CYCLOBUTANE-1-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS ATF4 INHIBITORS FOR TREATING CANCER AND OTHER DISEASES

The invention is directed to substituted bridged cycloalkane derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein X, a, b, C, D, L2,L3, Y1, Y2, R2, R4, R5, R6, z2, z4, z5, and z6 are as defined herein, and salts thereof. The invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to compounds for use in methods of inhibiting the ATF4 (activating transcription factor 4) pathway and treatment of disorders associated therewith, such as e.g. cancer, neurodegenerative diseases and many other diseases, using a compound of the invention or a pharmaceutical composition comprising a compound of the invention. Preferred compounds of the invention are N-(3-(2-(4-chlorophenoxy) acetamido)bicyclo[1.1.1]pentan-l-yl)-2-cyclobutane-l-carboxamide derivatives and related compounds.

Method for synthesizing high-content galbanum oxyacetate fragrance

The invention discloses a method for synthesizing a high-content galbanum oxyacetate fragrance. The method replaces the Williamson reaction, and includes perform an O-H insertion reaction of ethyl diazoacetate and cyclohexanol under catalysis of a catalyst Rh2(OAc)4 to obtain ethyl cyclohexyloxyacetate, saponifying and acidifying to obtain cyclohexyloxyacetic acid, and esterifying with allyl alcohol to obtain galbanum oxyacetate. The method can greatly shorten the reaction time. In addition, a prepared solid acid catalyst Yb-MoO3/Al2O3-ZrO2 has the advantages of easy separation from a liquid phase reaction system, no corrosion on equipment and simple post-treatment, which overcomes the problems of corrosion of the existing liquid acid on the equipment and pollution of acid-containing wastewater on the environment; the catalyst has high selectivity, and can be applied at low temperatures, so as to save energy consumption, reduce occurrence of side reactions, and can greatly improve production efficiency, and the content of the prepared galbanum oxyacetate fragrance is as high as 99.6%; and the catalyst is good in thermal stability, and active components are not easy to lose, so thecatalyst has good reusability and is a new green catalytic material with great application potentials.

Electrochemical methoxymethylation of alcohols-a new, green and safe approach for the preparation of MOM ethers and other acetals

A new, green, safe, cost-effective and highly efficient electrochemical approach for the methoxymethylation of alcohols and phenols was successfully developed. The methodology was also applied to the synthesis of substituted acetals.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The invention relates to the field of medicine, discloses new nitrogen heterocyclic derivatives, preparation method thereof and as medicament in particular as the treatment and prevention of treating tissue fibrosis of the medicament. The invention also discloses a pharmaceutically acceptable compound of the present invention comprise a pharmaceutical composition and methods for using the composition for the treatment of the human or animal tissue fibrosis of diseases, in particular for treating the human or animal renal interstitial fibrosis, glomerular sclerosis, hepatic fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, after the operation of adhering, benign prostate hypertrophy, bone-myocardial, scleroderma, multiple sclerosis, pancreas fibrosis, liver cirrhosis, myosarcoma, neurofibromatosis, interstitial pulmonary fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease in use. (by machine translation)

Nitrogenous Heterocyclic Derivatives And Their Application In Drugs

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5- mediated disorders are also described.

NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.